Lopinavir ritonavir indications and usage

Jump to navigation Jump to search
Lopinavir ritonavir
KALETRA ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Indications and Usage

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older).

The following points should be considered when initiating therapy with KALETRA:

  • The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Microbiology (12.4) and Clinical Studies (14)].
  • Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA [see Microbiology (12.4)]. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA [see Microbiology].[1]


References

  1. "KALETRA (LOPINAVIR AND RITONAVIR) TABLET, FILM COATED KALETRA (LOPINAVIR AND RITONAVIR) SOLUTION [ABBVIE INC.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.